On May 20, 2026 4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, reported that it has signed a Clinical Supply Agreement with a leading cancer immunotherapy innovator ("the Client") to provide GMP-grade opDNA starting material for its latest clinical programme.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, 4basebio will supply synthetic DNA to be used as a critical material for the Client’s immunotherapy candidate for an upcoming Phase II clinical trial. The agreement is expected to provide an approximate seven-figure revenue stream over the next 12 months, reflecting 4basebio’s unique capability to provide a safer, cost-effective replacement for plasmid DNA in the development of genetic medicines.
By leveraging 4basebio’s enzymatic, cell-free manufacturing process, the Client will enhance the safety of its therapeutic product by fully eliminating microbial contamination and the inclusion of antibiotic resistance genes, helping to accelerate its development timelines from sequence to clinic.
Dr. Amy Walker, Chief Executive Officer at 4basebio, added: "This partnership demonstrates how our proprietary DNA technology platform can help clients overcome complex manufacturing hurdles and bring safer and effective therapies to patients. We continue to see growing interest in our DNA molecules across the genetic medicine space and are delighted to support our partners through their clinical trials."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.
(Press release, 4basebio, MAY 20, 2026, View Source [SID1234665908])